These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37823411)

  • 1. Systematic review with meta-analysis: Diagnostic performance of faecal calprotectin in distinguishing inflammatory bowel disease from irritable bowel syndrome in adults.
    Dajti E; Frazzoni L; Iascone V; Secco M; Vestito A; Fuccio L; Eusebi LH; Fusaroli P; Rizzello F; Calabrese C; Gionchetti P; Bazzoli F; Zagari RM
    Aliment Pharmacol Ther; 2023 Dec; 58(11-12):1120-1131. PubMed ID: 37823411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Kandala NB; Shyangdan D; Arasaradnam R; Clar C; Johnston R
    Health Technol Assess; 2013 Nov; 17(55):xv-xix, 1-211. PubMed ID: 24286461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Significance of Faecal Calprotectin in Differentiating Inflammatory Bowel Disease from Irritable Bowel Syndrome.
    Chowdhury MFK; Ghosh CK; Miah MSA; Uddin MA; Rassell M; Rashid MH; Pal AK; Mahabub-Uz-Zaman K; Saha KP; Miah MAR
    Mymensingh Med J; 2024 Oct; 33(4):1149-1156. PubMed ID: 39351737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Performance of a Novel LIAISON Fecal Calprotectin Assay for Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome.
    Campbell JP; Zierold C; Rode AM; Blocki FA; Vaughn BP
    J Clin Gastroenterol; 2021 Mar; 55(3):239-243. PubMed ID: 32324678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome.
    Chang MH; Chou JW; Chen SM; Tsai MC; Sun YS; Lin CC; Lin CP
    Mol Med Rep; 2014 Jul; 10(1):522-6. PubMed ID: 24788223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome.
    Kaiser T; Langhorst J; Wittkowski H; Becker K; Friedrich AW; Rueffer A; Dobos GJ; Roth J; Foell D
    Gut; 2007 Dec; 56(12):1706-13. PubMed ID: 17675327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Faecal calprotectin testing for identifying patients with organic gastrointestinal disease: systematic review and meta-analysis.
    An YK; Prince D; Gardiner F; Neeman T; Linedale EC; Andrews JM; Connor S; Begun J
    Med J Aust; 2019 Nov; 211(10):461-467. PubMed ID: 31680263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prevalence of irritable bowel syndrome-type symptoms in paediatric inflammatory bowel disease, and the relationship with biochemical markers of disease activity.
    Diederen K; Hoekman DR; Hummel TZ; de Meij TG; Koot BG; Tabbers MM; Vlieger AM; Kindermann A; Benninga MA
    Aliment Pharmacol Ther; 2016 Jul; 44(2):181-8. PubMed ID: 27110920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Faecal calprotectin as a diagnostic marker of inflammatory bowel disease in patients with gastrointestinal symptoms: meta-analysis.
    Petryszyn P; Staniak A; Wolosianska A; Ekk-Cierniakowski P
    Eur J Gastroenterol Hepatol; 2019 Nov; 31(11):1306-1312. PubMed ID: 31464777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of non-invasive biomarkers faecal BAFF, calprotectin and FOBT in discriminating IBS from IBD and evaluation of intestinal inflammation.
    Fu Y; Wang L; Xie C; Zou K; Tu L; Yan W; Hou X
    Sci Rep; 2017 Jun; 7(1):2669. PubMed ID: 28572616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Semiquantitative fecal calprotectin test in postinfectious and non-postinfectious irritable bowel syndrome: cross-sectional study.
    David LE; Surdea-Blaga T; Dumitrascu DL
    Sao Paulo Med J; 2015; 133(4):343-9. PubMed ID: 26039537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of two immunoassays for measurement of faecal calprotectin in detection of inflammatory bowel disease: (pre)-analytical and diagnostic performance characteristics.
    Oyaert M; Trouvé C; Baert F; De Smet D; Langlois M; Vanpoucke H
    Clin Chem Lab Med; 2014 Mar; 52(3):391-7. PubMed ID: 24114912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Calprotectin, IL-6, and CRP in Distinguishing Between Inflammatory Bowel Disease and Diarrhea Predominant Irritable Bowel Syndrome.
    Huong BT; Hien NM; Dung NT; Quang DM; Vinh NT; Tu TT; Chi TK; Phuong LB; Nhan NT
    Med Arch; 2024; 78(2):105-111. PubMed ID: 38566874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary care faecal calprotectin testing in children with suspected inflammatory bowel disease: a diagnostic accuracy study.
    Walker GJ; Chanchlani N; Thomas A; Lin S; Moore L; Heerasing NM; Hendy P; Abdelrahim M; Mole S; Perry MH; Mcdonald TJ; Bewshea CM; Hart JW; Russell RK; Ahmad T; Goodhand JR; Kennedy NA
    Arch Dis Child; 2020 Oct; 105(10):957-963. PubMed ID: 32424002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS.
    Menees SB; Powell C; Kurlander J; Goel A; Chey WD
    Am J Gastroenterol; 2015 Mar; 110(3):444-54. PubMed ID: 25732419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic accuracy and clinical application of faecal calprotectin in adult patients presenting with gastrointestinal symptoms in primary care.
    Pavlidis P; Chedgy FJ; Tibble JA
    Scand J Gastroenterol; 2013 Sep; 48(9):1048-54. PubMed ID: 23883068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic utility of faecal biomarkers in patients with irritable bowel syndrome.
    Däbritz J; Musci J; Foell D
    World J Gastroenterol; 2014 Jan; 20(2):363-75. PubMed ID: 24574706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of faecal calprotectin assay variability on the management of inflammatory bowel disease and potential role of faecal S100A12.
    Whitehead SJ; Ford C; Gama RM; Ali A; McKaig B; Waldron JL; Steed H; Brookes MJ
    J Clin Pathol; 2017 Dec; 70(12):1049-1056. PubMed ID: 28735301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
    D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
    Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome.
    Otten CM; Kok L; Witteman BJ; Baumgarten R; Kampman E; Moons KG; de Wit NJ
    Clin Chem Lab Med; 2008; 46(9):1275-80. PubMed ID: 18597588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.